Erratum: Tofacitinib: A review of its use in adult patients with rheumatoid arthritis (Drugs (2013) 73 (857-874) DOI:10.1007/s40265-013-0065-8);Tofacitinib: A review of its use in adult patients with rheumatoid arthritis

Drugs

Volumn 73, Issue 8, 2013, Pages 857-874

  Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ATORVASTATIN; AZATHIOPRINE; C REACTIVE PROTEIN; CYCLOSPORIN A; CYTOKINE RECEPTOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETHINYLESTRADIOL; FLUCONAZOLE; INTERLEUKIN 10; INTERLEUKIN 8; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; KETOCONAZOLE; LEVONORGESTREL; METFORMIN; METHOTREXATE; MIDAZOLAM; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE TYK2; STROMELYSIN; TOFACITINIB;

BREAST CANCER; CELL DIFFERENTIATION; COLORECTAL CANCER; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HEADACHE; HEMATOPOIESIS; HUMAN; HYPERTENSION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; KIDNEY CARCINOMA; LONG TERM CARE; LUNG CANCER; LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MELANOMA; NONHUMAN; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SINGLE DRUG DOSE; STOMACH CANCER; TH17 CELL; TH2 CELL; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 84878946619     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0122-3     Document Type: Erratum

References (71)

1. Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet. 2010;376(9746):1094-108.
2. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-19.
3. Centers for Disease Control and Prevention. Rheumatoid arthritis. 2012. http://www.cdc.gov/arthritis/basics/rheumatoid.htm. Accessed 22 Mar 2013.
4. Wilkie WS, Schwieterman P. Strategies for the management of rheumatoid arthritis. Orthopedics. 2012;35(2):125-30.
5. Singh JA, Furst DE, Bharat A, et al. 2012 update of 2008 American College of Rheumatology recommendations for use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64(5):625-39.
6. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs [Erratum appears in Ann Rheum Dis. 2011;70(8):1519]. Ann Rheum Dis. 2010;69(8):964-75.
7. Deighton C, O'Mahony R, Tosh J, et al. Management of rheumatoid arthritis: summary of NICE guidance. BMJ. 2009;338:710-2.
8. Emery P, Dorner T. Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. Ann Rheum Dis. 2011;70(12):2063-70.
9. Agarwal SK. Biologic agents in rheumatoid arthritis: an update for managed care professionals. J Manag Care Pharm. 2011;17(9 Suppl. B):S14-8.
10. Smolen JS, Aletaha D, Bijlsma JWJ, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631-7.
11. Tanaka Y, Maeshima Y, Yamaoka K. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis. Ann Rheum Dis. 2012;71(Suppl 2):i70-4.
12. Kontzias A, Laurence A, Gadina M, et al. Kinase inhibitors in the treatment of immune-mediated disease. F1000 Med Rep. 2012;4(5). doi: 10.3410/M4-5.
13. Kontzias A, Kotlyar A, Laurence A, et al. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol. 2012;12(4):464-70.
14. Flanagan ME, Blumenkopf TA, Brissette WH, et al. Discovery of CP-690,550: a potent and selective Janus kinase inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem. 2010;53(24):8468-84.
15. Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186(7):4234-43.
16. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26(1):127-32.
17. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003;302(5646):875- 8.
18. Pfizer Inc. XELJANZ® (tofacitinib) tablets for oral administration: US prescribing information. 2012. http://labeling.pfizer.com/ShowLabeling.aspx? id=959. Accessed 11 Mar 2013.
19. Migita K, Koga T, Komori A, et al. Influence of Janus kinase inhibition on interleukin 6-mediated induction of acute-phase serum amyloid A in rheumatoid synovium. J Rheumatol. 2011;38(11):2309-17.
20. Maeshima K, Yamaoka K, Kubo S, et al. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells. Arthritis Rheum. 2012;64(6):1790-8.
21. Rosengren S, Corr M, Firestein GS, et al. The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann Rheum Dis. 2012;71(3):440-7.
22. Kudlacz E, Perry B, Sawyer P, et al. The novel JAK3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am J Transplant. 2004;4(1):51-7.
23. Milici AJ, Kudlacz EM, Audoly L, et al. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther. 2008;10(1):R14.
24. Yamaoka K, Kubo S, Sonomoto K, et al. A JAK inhibitor, tofacitinib reduces IL-6 and matrix metalloproteinase-3 production in rheumatoid arthritis with suppressed cartilage destruction [abstract]. Arthritis Res Ther. 2012;14(Suppl. 1):77.
25. Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate repsonse to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381(9865):451-60.
26. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495-507.
27. McInnes IB, Kim H-Y, Lee S-H, et al. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. Ann Rheum Dis. 2013. doi: 10.1136/annrheumdis-2012-202442.
28. Winthrop KL, Racewicz A, Lee EB, et al. Evaluation of influenza and pneumococcal vaccine responses in patients with rheumatoid arthritis receiving tofacitinib [abstract no. 1284]. Arthritis Rheum. 2012;64(10 Suppl.):S550.
29. Gupta P, Stock TC, Wang R, et al. A phase 1 study to estimate the absolute oral bioavailability of tofacitinib (CP-690,550) in healthy subjects [abstract no. 1122902]. J Clin Pharmacol. 2011;51(9):1348.
30. Menon S, Boy MG, Wang C, et al. Single and multiple-dose pharmacokinetics of tofacitinib (CP-690,550) from a double-blind, placebo-controlled, dose-escalation study in medically stable subjects with psoriasis [abstract no. PI-70]. Clin Pharmacol Ther. 2012;91(Suppl. 1):S33.
31. Lamba M, Wang R, Stock T, et al. The effect of food on the pharmacokinetics of tofacitinib (CP-690,550) [abstract no. PI-74]. Clin Pharmacol Ther. 2012;91(Suppl. 1):S35.
32. Krishnaswami S, Wang T, Yuan Y, et al. Single and multiple dose pharmacokinetics of tofacitinib (CP-690,550) in healthy chinese volunteers [abstract no. PII-63]. Clin Pharmacol Ther. 2012;91(Suppl. 1):S75-S6.
33. Gupta P, Alvey C, Wang R, et al. Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data. Br J Clin Pharmacol. 2012;74(1):109-15.
34. Cohen S, Zwillich SH, Chow V, et al. Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment. Br J Clin Pharmacol. 2010;69(2):143-51.
35. Menon S, Riese R, Wang R, et al. The effect of tofacitinib (CP-690,550) on the pharmacokinetics of oral contraceptive steroids in healthy female volunteers [abstract no. PI-71]. Clin Pharmacol Ther. 2012;91(Suppl. 1):S33-43.
36. Gupta P, Wang R, Kaplan I, et al. A Phase 1 study to estimate the effect of ketoconazole on the pharmacokinetics of tofacitinib (CP-690,550) in healthy volunteers [abstract no. PI-64]. Clin Pharmacol Ther. 2012;91(Suppl. 1):S31.
37. Lamba M, Wang R, Kaplan I, et al. The effect of rifampin on the pharmacokinetics of tofacitinib (CP-690,550) in healthy volunteers [abstract no. PI-73]. Clin Pharmacol Ther. 2012;91(Suppl. 1):S35.
38. Kremer JM, Cohen S, Wilkinson BE, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 2012;64(4):970-81.
39. Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 2012;64(3):617-29.
40. Coombs JH, Bloom BJ, Breedveld FC, et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2010;69(2):413-6.
41. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 2009;60(7):1895-905.
42. Van Der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from the twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65(3):559-70.
43. Kremer J, Li Z-G, Hall S, et al. Tofacitinib (CP-690,550), an oral JAK inhibitor, in combination with traditional DMARDs: phase 3 study in patients with active rheumatoid arthritis with inadequate response to DMARDs [abstract no. LB0005]. Proceedings of the 12th Annual Congress of the European League Against Rheumatism, 25-28 May 2011, London.
44. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508-19.
45. Tanaka Y, Suzuki M, Nakamura H, et al. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res. 2011;63(8):1150-8.
46. Tanaka Y, Takeuchi T, Yamanaka H, et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week phase 2b study [abstract]. Arthritis Rheum. 2011;63(10 Suppl. 1):2192.
47. Pfizer Inc. Tofacitinib for rheumatoid arthritis: Advisory Committee Meeting submission. 2012. http://www.fda.gov/downloads/AdvisoryCommittees/ ComitteesMeetingMaterials/drugs/ArthritisAdvisoryComittee/UCM304200.pdf. Accessed 30 Jan 2013.
48. Pfizer. A study comparing 2 doses of CP-690,550 vs. placebo for the treatment of rheumatoid arthritis in patients on other background arthritis medications [ClinicalTrials.gov identifier NCT00856544]. US National Institutes of Health, ClinicalTrials.gov. 2012. http://clinicaltrials.gov. Accessed 27 Feb 2013.
49. Al-Maini M, Li ZG, Liu Y, et al. Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: summary of five Phase 3 studies [abstract no. 703521]. Int J Rheum Dis. 2012;15(Suppl. 1):67.
50. Pfizer. Long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis [ClinicalTrials.gov identifier NCT00413699]. US National Institutes of Health, ClinicalTrials.gov. 2012. http:// clinicaltrials.gov. Accessed 11 Feb 2013.
51. Yamanaka H, Tanaka Y, Takeuchi T, et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, as monotherapy or with background methotrexate in Japanese patients with rheumatoid arthritis: a phase 2/3 long-term extension study [abstract]. Arthritis Rheum. 2011;63(10 Suppl. 1):1215.
52. Wollenhaupt J, Silverfield J, Lee EB, et al. Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: open-label, long-term extension studies up to 36 months [abstract no. 703530]. Int J Rheum Dis. 2012;15(Suppl. 1):68.
53. Wollenhaupt J, Silverfield JC, Lee EB, et al. Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: open-label, long-term extension safety and efficacy up to 48 months [abstract no. 1282]. Arthritis Rheum. 2012;64(10 Suppl.):S548.
54. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheunatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-24.
55. Van Vollenhoven RF, Krishnaswami S, Benda B, et al. Tofacitinib and adalimumab achieve similar rates of low disease activity in rheumatoid arthritis: lack of improvement in disease activity score by 3 months predicts low likelihood of low disease activity at 1 year [abstract no. 1297]. Arthritis Rheum. 2012;64(10 Suppl.):S556.
56. van der Heijde D, Tanaka Y, Fleischmann RM, et al. Tofacitinib, an oral Janus kinase inhibitor, in combination with methotrexate reduced the progression of structural damage in patients with rheumatoid arthritis: year 2 efficacy and safety results from a 24-month phase 3 study [abstract no. 1277]. Arthritis Rheum. 2012;64(10 Suppl.):S546.
57. Strand V, Scott DL, Emery P, et al. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol. 2005;32:590-61.
58. Cohen S, Radominski SC, Asavatanabodee P, et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of infections and all-cause mortality across Phase 3 and long-term extension studies in patients with rheumatoid arthritis [abstract no. 703531]. Int J Rheum Dis. 2012;15(Suppl. 1):68.
59. Winthrop KL, Park S-H, Gul A, et al. Tuberculosis and tofacitinib therapy in patients with rheumatoid arthritis [abstract no. 1278]. Arthritis Rheum. 2012;64(10 Suppl.):S547.
60. Winthrop KL, Valdez H, Mortensen E, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis [abstract no. 2490]. Arthritis Rheum. 2012;64(10 Suppl.):S1051.
61. Wollenhaupt J, Silverfield J, Lee EB, et al. Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid rthritis: open-label, long-term extension safety and efficacy up to 48 months [poster no. 1282]. American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, 9-14 Nov 2012, Washington (DC).
62. Mariette X, Curtis JR, Lee EB, et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical programme (poster no. THU0131). The European League Against Rheumatism Congress, 2-9 Jun 2012, Berlin.
63. Pfizer Pharmaceuticals Inc. Xeljanz® (tofacitinib citrate) approved in Japan for the treatment of adults with rheumatoid arthritis. 2013. http://pfizer.newshq.businesswire.com/print/node/2702. Accessed 24 Apr 2013.
64. Breedveld FC, Kalden JR. Appropriate and effective management of rheumatoid arthritis. Ann Rheum Dis. 2004;63:627-33.
65. National Institute for Health and Clinical Excellence. Quick reference guide rheumatoid arthritis: the management of rheumatoid arthritis in adults (NICE clinical guideline 79). 2009. http://www.nice.org.uk/nicemedia/live/12131/ 43329/43329.pdf. Accessed 19 Mar 2013.
66. European Medcines Agency. Refusal of the marketing authorisation for Xeljanz (tofacitinib). 2013. http://www.ema.europa.eu/docs/en-GB/document- library/Summary-of-opinion-Initial-authorisation/human/002542/WC500142485.pdf. Accessed 29 April 2013.
67. Balsa A, Garcia-Arias M. Is there place for nonbiological drugs in the treatment of rheumatoid arthritis? Ther Adv Musculoskelet Dis. 2010;2(6):307-13.
68. Ahadieh S, Checcchio T, Tensfeldt T, et al. Meta-analysis of malignancies, serious infections, and serious adverse events with tofacitinib or biologic treatment in rheumatoid arthritis clinical trials [abstract]. Arthritis Rheum. 2012;64(10 Suppl.):S726.
69. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, et al. Risk of malignancies in some patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308(9):898-908.
70. Park HJ, Ranganathan P. TNF-α antagonism and cancer risk in rheumatoid arthritis: is continued vigilance warranted? Discov Med. 2012;13(70):229-34.
71. Onel KB, Onel K. Anti-tumor necrosis factor therapy and cancer risk in patients with autoimmune disorders. Arthritis Care Res. 2010;62(7):1024-8.